Legal Proceedings (Details) (USD $)	3 Months Ended	9 Months Ended		9 Months Ended	12 Months Ended	9 Months Ended
	Apr. 03, 2011	Oct. 02, 2011	Jun. 28, 2009	Oct. 02, 2011 Merck [Member]	Jan. 02, 2011 Merck [Member]	Oct. 02, 2011 COBI [Member]	Oct. 02, 2011 Average Wholesale Price Litigation [Member] Civil penalties [Member]	Oct. 02, 2011 Risperdal [Member] Civil penalties [Member]	Oct. 02, 2011 Risperdal [Member] Plaintiffs	Oct. 02, 2011 Restitution [Member]	Oct. 02, 2011 LEVAQUIN [Member] Plaintiffs	Oct. 02, 2011 ASR [Member] Plaintiffs	Oct. 02, 2011 PINNACLE Acetabular Cup System [Member] Plaintiffs	Oct. 02, 2011 Pelvic meshes [Member] Plaintiffs	Oct. 02, 2011 CYPHER [Member] Plaintiffs	Oct. 02, 2011 DURAGESIC [Member] Plaintiffs
Loss Contingencies [Line Items]
Litigation Loss	$ 593,000,000						$ 6,500,000	$ 327,100,000		$ 45,000,000
Prior Percentage of contribution to income profit split				58.00%		42.00%
Percentage of revenue represented by retained territories				70.00%
Total of Mercks 2010 Revenue					2,800,000,000
Net litigation expense		73,000,000
Product Liability Contingency [Line Items]
Number of claimants									500		3,500	3,500	560	350	90	80
Legal Proceeding (Textuals) [Abstract]
Amount given to plaintiff by jury	482,000,000
Verdict in favor of the State's Attorney General and against Janssen and the Company		257,700,000
Litigation settlement pre judgment interest	111,000,000
Approximate damages initially awarded to Centocor, then subsequently reversed by the Court of Appeals			1,700,000,000
Assessed damages for alleged consumer fraud as to DURAGESIC and RISPERDAL		4,500,000
Settlement payment related fines disgorgement and interest		78,000,000
Percentage of revenue represented by relinquished territories		30.00%
One time payment received by Company		500,000,000
Fine paid for settlement of the criminal case		$ 85,000,000